indomethacin and Episcleritis studies

Indomethacin: A non-steroidal anti-inflammatory agent (NSAID) that inhibits CYCLOOXYGENASE, which is necessary for the formation of PROSTAGLANDINS and other AUTACOIDS. It also inhibits the motility of POLYMORPHONUCLEAR LEUKOCYTES.
indometacin : A member of the class of indole-3-acetic acids that is indole-3-acetic acid in which the indole ring is substituted at positions 1, 2 and 5 by p-chlorobenzoyl, methyl, and methoxy groups, respectively. A non-steroidal anti-inflammatory drug, it is used in the treatment of musculoskeletal and joint disorders including osteoarthritis, rheumatoid arthritis, gout, bursitis and tendinitis.

Research Excerpts

Excerpt	Relevance	Reference
"Six patients with diffuse or nodular scleritis that did not respond satisfactorily to oral indomethacin or prednisone used alone required a combination of these two drugs to achieve a complete clinical response."	7.67	Treatment of scleritis with combined oral prednisone and indomethacin therapy. ( Mondino, BJ; Phinney, RB, 1988)
"Posterior scleritis is a rare disease, the clinical signs of which may vary."	5.29	Recognition of posterior scleritis and its treatment with indomethacin. ( Robertson, JE; Rosenbaum, JT, 1993)
"Six patients with diffuse or nodular scleritis that did not respond satisfactorily to oral indomethacin or prednisone used alone required a combination of these two drugs to achieve a complete clinical response."	3.67	Treatment of scleritis with combined oral prednisone and indomethacin therapy. ( Mondino, BJ; Phinney, RB, 1988)
"Posterior scleritis is an unusual disease that may cause serious ocular inflammation and potentially blinding consequences."	1.34	Isolated bilateral posterior scleritis after eye trauma. ( Ramirez-Ortiz, MA; Vasquez-Resendis, A, 2007)
"Although scleritis has not been reported as a tubulointerstitial nephritis-associated ocular inflammation, it may be part of the possible spectrum of ocular inflammation occurring as part of the TINU syndrome."	1.33	Recurrent nodular scleritis preceding an adult TINU syndrome. ( Daniel, E; Gangaputra, S; Jabs, DA; Kempen, JH, 2006)
"Posterior scleritis has protean manifestations and can be easily overlooked."	1.32	[Posterior scleritis: six case reports]. ( Attia, S; Bhouri, L; Chaouch, K; Jelliti, B; Jenzri, S; Khairallah, M; Ladjimi, A; Messaoud, R; Zaouali, S, 2003)
"Scleritis is a severe ocular inflammation, often associated with ocular complications, and nearly always treated with systemic medications."	1.31	Episcleritis and scleritis: clinical features and treatment results. ( Dunn, JP; Jabs, DA; Marsh, MJ; Mudun, A, 2000)
"Posterior scleritis is a rare disease, the clinical signs of which may vary."	1.29	Recognition of posterior scleritis and its treatment with indomethacin. ( Robertson, JE; Rosenbaum, JT, 1993)
"Patients with colitis or ileocolitis were more likely to suffer from ocular inflammation (23."	1.28	Ocular inflammation in Crohn's disease. ( Murray, AD; Salmon, JF; Wright, JP, 1991)

Research

Studies (15)

Authors

Clinical Trials (3)

Trial Overview

Trial Outcomes

Mean Change in Intraocular Pressure in the Study Eye (or Eyes) at Final Safety Visit Compared to Baseline

Timeframe	Studies, this research(%)	All Research%
pre-1990	3 (20.00)	18.7374
1990's	4 (26.67)	18.2507
2000's	5 (33.33)	29.6817
2010's	3 (20.00)	24.3611
2020's	0 (0.00)	2.80

Authors	Studies
Moussa, K	1
Shantha, J	1
Schallhorn, JM	1
Takkar, B	1
Khokhar, S	1
Kumar, U	1
Venkatesh, P	1
Liu, AT	1
Luk, FO	1
Chan, CK	1
Ladjimi, A	1
Messaoud, R	1
Attia, S	1
Jenzri, S	1
Zaouali, S	1
Chaouch, K	1
Bhouri, L	1
Jelliti, B	1
Khairallah, M	1
Daniel, E	1
Gangaputra, S	1
Kempen, JH	1
Jabs, DA	2
Ramirez-Ortiz, MA	1
Vasquez-Resendis, A	1
Rosenbaum, JT	1
Robertson, JE	1
Chow, MT	1
Anderson, SF	1
Mudun, A	1
Dunn, JP	1
Marsh, MJ	1
Grapă, C	1
Salmon, JF	2
Wright, JP	1
Murray, AD	2
Strauss, PC	1
Todd, G	1
Lightman, S	1
Watson, P	1
Mondino, BJ	1
Phinney, RB	1
Guan, ZS	1
Zhong, GQ	1
Hu, ZK	1
Wu, ZY	1

Trial	Phase	Enrollment	Study Type	Start Date	Status
An Open Label, Multi-centered, Randomized Phase 2 Study to Evaluate the Safety, Tolerability and Bioactivity of Subcutaneous ACTH GeL in PAtients With Scleritis: The ATLAS Study[NCT03465111]	Phase 2	30 participants (Anticipated)	Interventional	2019-01-01	Recruiting
Gevokizumab Treatment for Active Scleritis By IL-1 Inhibition (GATSBY)[NCT01835132]	Phase 1/Phase 2	8 participants (Actual)	Interventional	2013-03-31	Completed
A Phase I/II Study to Investigate Subconjunctival Sirolimus for the Treatment of Active Autoimmune Non-Necrotizing Anterior Scleritis[NCT01517074]	Phase 1/Phase 2	5 participants (Actual)	Interventional	2012-01-31	Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Intraocular pressure (IOP) is measured in millimeters of mercury (mmHg). (NCT01835132)
Timeframe: Baseline and Final Visit

Mean Change in Intraocular Pressure in the Study Eye (or Eyes) at Week 12 Compared to Baseline

Intervention	mmHg (Mean)
Gevokizumab	1.33

Intraocular pressure (IOP) is measured in millimeters of mercury (mmHg). (NCT01835132)
Timeframe: Baseline and Week 12

Mean Change in Intraocular Pressure in the Study Eye (or Eyes) at Week 16 Compared to Baseline

Intervention	mmHg (Mean)
Gevokizumab	1.00

Intraocular pressure (IOP) is measured in millimeters of mercury (mmHg). (NCT01835132)
Timeframe: Baseline and Week 16

Mean Change in Intraocular Pressure in the Study Eye (or Eyes) at Week 2 Compared to Baseline

Intervention	mmHg (Mean)
Gevokizumab	1.56

Intraocular pressure (IOP) is measured in millimeters of mercury (mmHg). (NCT01835132)
Timeframe: Baseline and Week 2

Mean Change in Intraocular Pressure in the Study Eye (or Eyes) at Week 20 Compared to Baseline

Intervention	mmHg (Mean)
Gevokizumab	0.67

Intraocular pressure (IOP) is measured in millimeters of mercury (mmHg). (NCT01835132)
Timeframe: Baseline and Week 20

Mean Change in Intraocular Pressure in the Study Eye (or Eyes) at Week 24 Compared to Baseline

Intervention	mmHg (Mean)
Gevokizumab	1.33

Mean Change in Intraocular pressure (IOP) is measured and reported as change in IOP between baseline and 24 weeks in millimeters of mercury (mmHg). (NCT01835132)
Timeframe: Baseline and Week 24

Mean Change in Intraocular Pressure in the Study Eye (or Eyes) at Week 28 Compared to Baseline

Intervention	mmHg (Mean)
Gevokizumab	0.78

Intraocular pressure (IOP) is measured in millimeters of mercury (mmHg). (NCT01835132)
Timeframe: Baseline and Week 28

Mean Change in Intraocular Pressure in the Study Eye (or Eyes) at Week 32 Compared to Baseline

Intervention	mmHg (Mean)
Gevokizumab	1.11

Intraocular pressure (IOP) is measured in millimeters of mercury (mmHg). (NCT01835132)
Timeframe: Baseline and Week 32

Mean Change in Intraocular Pressure in the Study Eye (or Eyes) at Week 36 Compared to Baseline

Intervention	mmHg (Mean)
Gevokizumab	2.67

Intraocular pressure (IOP) is measured in millimeters of mercury (mmHg). (NCT01835132)
Timeframe: Baseline and Week 36

Mean Change in Intraocular Pressure in the Study Eye (or Eyes) at Week 4 Compared to Baseline

Intervention	mmHg (Mean)
Gevokizumab	2.17

Intraocular pressure (IOP) is measured in millimeters of mercury (mmHg). (NCT01835132)
Timeframe: Baseline and Week 4

Mean Change in Intraocular Pressure in the Study Eye (or Eyes) at Week 40 Compared to Baseline

Intervention	mmHg (Mean)
Gevokizumab	0.67

Intraocular pressure (IOP) is measured in millimeters of mercury (mmHg). (NCT01835132)
Timeframe: Baseline and Week 40

Mean Change in Intraocular Pressure in the Study Eye (or Eyes) at Week 52 Compared to Baseline

Intervention	mmHg (Mean)
Gevokizumab	0.50

Intraocular pressure (IOP) is measured in millimeters of mercury (mmHg). (NCT01835132)
Timeframe: Baseline and Week 52

Mean Change in Intraocular Pressure in the Study Eye (or Eyes) at Week 52A Compared to Baseline

Intervention	mmHg (Mean)
Gevokizumab	1.83

"This visit represents the beginning of the as-needed 2nd Extension Phase at Week 52. If eligible, participants continued with injections at Wks 52, 54, 58 and 62.~Intraocular pressure (IOP) is measured in millimeters of mercury (mmHg)." (NCT01835132)
Timeframe: Baseline and Week 52A

Mean Change in Intraocular Pressure in the Study Eye (or Eyes) at Week 54 Compared to Baseline

Intervention	mmHg (Mean)
Gevokizumab	-0.67

Intraocular pressure (IOP) is measured in millimeters of mercury (mmHg). (NCT01835132)
Timeframe: Baseline and Week 54

Mean Change in Intraocular Pressure in the Study Eye (or Eyes) at Week 58 Compared to Baseline

Intervention	mmHg (Mean)
Gevokizumab	1.33

Intraocular pressure (IOP) is measured in millimeters of mercury (mmHg). (NCT01835132)
Timeframe: Baseline and Week 58

Mean Change in Intraocular Pressure in the Study Eye (or Eyes) at Week 62 Compared to Baseline

Intervention	mmHg (Mean)
Gevokizumab	1.33

Intraocular pressure (IOP) is measured in millimeters of mercury (mmHg). (NCT01835132)
Timeframe: Baseline and Week 62

Mean Change in Intraocular Pressure in the Study Eye (or Eyes) at Week 8 Compared to Baseline

Intervention	mmHg (Mean)
Gevokizumab	0.67

Intraocular pressure (IOP) is measured in millimeters of mercury (mmHg). (NCT01835132)
Timeframe: Baseline and Week 8

Mean Change in Visual Acuity in the Study Eye (or Eyes) at Final Safety Visit Compared to Baseline

Intervention	mmHg (Mean)
Gevokizumab	1.11

Visual acuity was measured using the Early Treatment Diabetic Retinopathy Study (ETDRS) protocol. Acuity is measured as letters read on an ETDRS eye chart and the letters read equate to Snellen measurements. For example, if a participant reads between 84 and 88 letters, the equivalent Snellen measurement is 20/20. (NCT01835132)
Timeframe: Baseline and Final Visit

Mean Change in Visual Acuity in the Study Eye (or Eyes) at Week 12 Compared to Baseline

Intervention	ETDRS letters (Mean)
Gevokizumab	-2.00

Mean Change in Visual Acuity in the Study Eye (or Eyes) at Week 16 Compared to Baseline

Intervention	ETDRS letters (Mean)
Gevokizumab	0.11

Mean Change in Visual Acuity in the Study Eye (or Eyes) at Week 2 Compared to Baseline

Intervention	ETDRS letters (Mean)
Gevokizumab	1.00

Mean Change in Visual Acuity in the Study Eye (or Eyes) at Week 20 Compared to Baseline

Intervention	ETDRS letters (Mean)
Gevokizumab	-1.00

Mean Change in Visual Acuity in the Study Eye (or Eyes) at Week 24 Compared to Baseline

Intervention	ETDRS letters (Mean)
Gevokizumab	1.33

Mean Change in Visual Acuity in the Study Eye (or Eyes) at Week 28 Compared to Baseline

Intervention	ETDRS letters (Mean)
Gevokizumab	-0.67

Mean Change in Visual Acuity in the Study Eye (or Eyes) at Week 32 Compared to Baseline

Intervention	ETDRS letters (Mean)
Gevokizumab	1.00

Mean Change in Visual Acuity in the Study Eye (or Eyes) at Week 36 Compared to Baseline

Intervention	ETDRS letters (Mean)
Gevokizumab	3.00

Mean Change in Visual Acuity in the Study Eye (or Eyes) at Week 4 Compared to Baseline

Intervention	ETDRS letters (Mean)
Gevokizumab	1.83

Mean Change in Visual Acuity in the Study Eye (or Eyes) at Week 40 Compared to Baseline

Intervention	ETDRS letters (Mean)
Gevokizumab	-1.78

Mean Change in Visual Acuity in the Study Eye (or Eyes) at Week 52 Compared to Baseline

Intervention	ETDRS letters (Mean)
Gevokizumab	2.67

Mean Change in Visual Acuity in the Study Eye (or Eyes) at Week 52A Compared to Baseline

Intervention	ETDRS letters (Mean)
Gevokizumab	0.17

"This visit represents the beginning of the as-needed 2nd Extension Phase at Week 52. If eligible, participants continued with injections at Wks 52, 54, 58 and 62.~Visual acuity was measured using the Early Treatment Diabetic Retinopathy Study (ETDRS) protocol. Acuity is measured as letters read on an ETDRS eye chart and the letters read equate to Snellen measurements. For example, if a participant reads between 84 and 88 letters, the equivalent Snellen measurement is 20/20." (NCT01835132)
Timeframe: Baseline and Week 52A

Mean Change in Visual Acuity in the Study Eye (or Eyes) at Week 54 Compared to Baseline

Intervention	ETDRS letters (Mean)
Gevokizumab	-8.00

Mean Change in Visual Acuity in the Study Eye (or Eyes) at Week 58 Compared to Baseline

Intervention	ETDRS letters (Mean)
Gevokizumab	-0.67

Mean Change in Visual Acuity in the Study Eye (or Eyes) at Week 62 Compared to Baseline

Intervention	ETDRS letters (Mean)
Gevokizumab	-1.33

Mean Change in Visual Acuity in the Study Eye (or Eyes) at Week 8 Compared to Baseline

Intervention	ETDRS letters (Mean)
Gevokizumab	-1.33

Number of Participants With at Least a 2-step Reduction or Reduction to Grade 0 in Scleral Inflammation in the Study Eye (or Eyes), According to the National Eye Institute (NEI) Photographic Scleritis Grading System, on or Before the Week 16 Visit.

Intervention	ETDRS letters (Mean)
Gevokizumab	0.78

Scleral inflammation was graded following 10% Phenylephrine application with an ordinal scale of 0 (no scleral inflammation with complete blanching of vessels), 0.5+ (minimal/trace inflammation with localized pink appearance of the sclera around minimally dilated deep episcleral vessels), 1+ (mild inflammation with diffuse pink appearance of the sclera around mildly dilated deep episcleral vessels), 2+ (moderate inflammation with purplish pink appearance of the sclera with tortuous and engorged deep episcleral vessels), 3+ (severe inflammation with diffuse significant redness of sclera, the details of superficial and deep episcleral vessels can't be observed), and 4+ (necrotizing inflammation with diffuse redness of the sclera with scleral thinning and uveal show). (NCT01835132)
Timeframe: Baseline and Week 16

Number of Participants With Loss of ≥ 15 Early Treatment Diabetic Retinopathy Study (ETDRS) Letters

Intervention	participants (Number)
Gevokizumab	6

Mean Change in Visual Acuity Via the Early Treatment Diabetic Retinopathy Study (ETDRS)

Intervention	participants (Number)
Gevokizumab	0

Mean Number of Days Between the First Injection to the Second Injection

Intervention	letters read (Mean)
Study Eye	-0.25
Fellow Eye	-2.25

For participants who demonstrate active inflammation (incomplete or no response to initial injection) or experience a flare-up (as defined by a ≥1-step increase in scleral inflammation) after the initial injection (NCT01517074)
Timeframe: Baseline and Week 52

Median Change in Visual Acuity Via the Early Treatment Diabetic Retinopathy Study (ETDRS)

Intervention	Days (Mean)
Sirolimus	65.3

Number of Participants Needing a Second Injection

Intervention	letters read (Median)
Study Eye	0.00
Fellow Eye	-2.50

Participants that still demonstrate active inflammation (incomplete or no response to initial injection) or experience a flare-up (as defined by a ≥1-step increase in scleral inflammation) after the initial injection will be eligible for a re-injection in the study eye at or after Week 4 (not to exceed a dose of 1,320 μg per eye within an eight-week period). (NCT01517074)
Timeframe: Baseline and Week 52

Number of Participants Who Experience a Disease Flare as Defined by a ≥ 1-step Increase in Scleral Inflammation

Intervention	participants (Number)
Sirolimus	3

Number of Participants Who Experience a Substantial Rise in Elevated Intraocular Pressure (IOP)

Intervention	participants (Number)
Sirolimus	3

A substantial rise in intraocular pressure can be defined as ≥10 mmHg change in pressure. (NCT01517074)
Timeframe: Baseline and Week 52

Number of Participants Who Experience at Least 2-step Reduction or Reduction to Grade 0 of Scleral Inflammation in the Study Eye According to the National Eye Institute (NEI) Photographic Scleritis Grading System Within 8 Weeks Post-injection.

Intervention	participants (Number)
Sirolimus	0

"The primary efficacy outcome was a 2-step reduction in scleritis grading out of a scale of 0 to 4+ (where 0.5+ is recognized as an ordinal step between 1+ and 0+).~Scleral inflammation was graded following 10% Phenylephrine application with an ordinal scale of 0 (no scleral inflammation with complete blanching of vessels), 0.5+ (minimal/trace inflammation with localized pink appearance of the sclera around minimally dilated deep episcleral vessels), 1+ (mild inflammation with diffuse pink appearance of the sclera around mildly dilated deep episcleral vessels), 2+ (moderate inflammation with purplish pink appearance of the sclera with tortuous and engorged deep episcleral vessels), 3+ (severe inflammation with diffuse significant redness of sclera, the details of superficial and deep episcleral vessels can't be observed), and 4+ (necrotizing inflammation with diffuse redness of the sclera with scleral thinning and uveal show)." (NCT01517074)
Timeframe: Baseline and Week 8

Number of Participants Who Experienced Ocular Toxicities

Number of Participants Who Experienced Systemic Toxicities

Number of Participants Who Tapered Off One or More Systemic Immunosuppressive Medications or Tapered Off Prednisone (≤10 mg) After Week 16

Intervention	participants (Number)
Sirolimus	5

Intervention	participants (Number)
Sirolimus	2

Intervention	participants (Number)
Sirolimus	0

Four (4) out of 5 participants were on immunosuppressive medications at enrollment. (NCT01517074)
Timeframe: Week 16 and Week 52

Proportion of Participants With Loss of ≥ 15 Early Treatment Diabetic Retinopathy Study (ETDRS) Letters

Intervention	participants (Number)
Sirolimus	1

Step Changes in Scleral Inflammation According to the Standardized Photographic Grading System Developed at National Eye Institute (NEI)

Intervention	score on a scale (Number)
	Participant 001	Participant 002	Participant 003	Participant 005
Scleral Inflammation Score at Baseline	3	1	3	3
Scleral Inflammation Score at Week 52	0	0	0	0
Step Changes in Scleral Inflammation at Week 52 From Baseline	-4	-2	-4	-4

Article	Year
Blurry Vision and Eye Pain After Pterygium Surgery. JAMA ophthalmology, 2018, 07-01, Volume: 136, Issue:7 Topics: Administration, Oral; Aged; Anti-Bacterial Agents; Anti-Inflammatory Agents, Non-Steroidal; Eye Infe	2018
Necrotising scleritis, keratitis and uveitis in primary antiphospholipid syndrome. BMJ case reports, 2018, May-14, Volume: 2018 Topics: Administration, Oral; Administration, Topical; Anti-Inflammatory Agents, Non-Steroidal; Antiphosphol	2018
A case of giant nodular posterior scleritis mimicking choroidal malignancy. Indian journal of ophthalmology, 2015, Volume: 63, Issue:12 Topics: Administration, Oral; Adult; Anti-Inflammatory Agents, Non-Steroidal; Choroid Neoplasms; Diagnosis,	2015
[Posterior scleritis: six case reports]. Journal francais d'ophtalmologie, 2003, Volume: 26, Issue:8 Topics: Administration, Oral; Adolescent; Adrenal Cortex Hormones; Adult; Anti-Inflammatory Agents; Anti-Inf	2003
Recurrent nodular scleritis preceding an adult TINU syndrome. Ocular immunology and inflammation, 2006, Volume: 14, Issue:4 Topics: Acute Disease; Female; Glucocorticoids; Humans; Indomethacin; Middle Aged; Nephritis, Interstitial;	2006
Isolated bilateral posterior scleritis after eye trauma. Journal of AAPOS : the official publication of the American Association for Pediatric Ophthalmology and Strabismus, 2007, Volume: 11, Issue:3 Topics: Azathioprine; Child; Conjunctiva; Drug Therapy, Combination; Eye Injuries; Eyelids; Female; Fluoresc	2007
Recognition of posterior scleritis and its treatment with indomethacin. Retina (Philadelphia, Pa.), 1993, Volume: 13, Issue:1 Topics: Adult; Female; Fluorescein Angiography; Follow-Up Studies; Fundus Oculi; Humans; Indomethacin; Male;	1993
Relapsing polychondritis. Optometry and vision science : official publication of the American Academy of Optometry, 2000, Volume: 77, Issue:6 Topics: Aged; Aged, 80 and over; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Choroid	2000
Episcleritis and scleritis: clinical features and treatment results. American journal of ophthalmology, 2000, Volume: 130, Issue:4 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-	2000
Episcleritis and scleritis: clinical features and treatment results. American journal of ophthalmology, 2000, Volume: 130, Issue:4 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-	2000
Episcleritis and scleritis: clinical features and treatment results. American journal of ophthalmology, 2000, Volume: 130, Issue:4 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-	2000
Episcleritis and scleritis: clinical features and treatment results. American journal of ophthalmology, 2000, Volume: 130, Issue:4 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-	2000
Episcleritis and scleritis: clinical features and treatment results. American journal of ophthalmology, 2000, Volume: 130, Issue:4 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-	2000
Episcleritis and scleritis: clinical features and treatment results. American journal of ophthalmology, 2000, Volume: 130, Issue:4 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-	2000
Episcleritis and scleritis: clinical features and treatment results. American journal of ophthalmology, 2000, Volume: 130, Issue:4 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-	2000
Episcleritis and scleritis: clinical features and treatment results. American journal of ophthalmology, 2000, Volume: 130, Issue:4 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-	2000
Episcleritis and scleritis: clinical features and treatment results. American journal of ophthalmology, 2000, Volume: 130, Issue:4 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-	2000
[Palindromic posterior scleritis]. Oftalmologia (Bucharest, Romania : 1990), 1991, Volume: 35, Issue:3-4 Topics: Diagnosis, Differential; Drug Therapy, Combination; Female; Humans; Hydrocortisone; Indomethacin; Mi	1991
Ocular inflammation in Crohn's disease. Ophthalmology, 1991, Volume: 98, Issue:4 Topics: Adolescent; Adult; Aged; Anterior Eye Segment; Anti-Inflammatory Agents, Non-Steroidal; Child; Colit	1991
Acute scleritis in porphyria cutanea tarda. American journal of ophthalmology, 1990, Apr-15, Volume: 109, Issue:4 Topics: Acute Disease; Aged; Bloodletting; Female; Humans; Indomethacin; Male; Middle Aged; Porphyrias; Porp	1990
Treatment of scleritis with combined oral prednisone and indomethacin therapy. American journal of ophthalmology, 1989, Jul-15, Volume: 108, Issue:1 Topics: Administration, Oral; Drug Therapy, Combination; Humans; Indomethacin; Prednisone; Scleritis	1989
Treatment of scleritis with combined oral prednisone and indomethacin therapy. American journal of ophthalmology, 1988, Oct-15, Volume: 106, Issue:4 Topics: Administration, Oral; Drug Combinations; Female; Humans; Indomethacin; Male; Middle Aged; Prednisone	1988
[Treatment of necrotising scleritis]. Yan ke xue bao = Eye science, 1988, Volume: 4, Issue:3 Topics: Adult; Aged; Combined Modality Therapy; Cyclophosphamide; Drug Therapy, Combination; Female; Humans;	1988

indomethacin and Episcleritis